Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine controlling and curing chronic aplastic anemia

A technology for aplastic anemia and drugs, applied in drug combinations, blood diseases, pharmaceutical formulations, etc., can solve the problems of poor thrombocytopenia, long-term complications, and inability to cure, and achieve hematopoietic microenvironment regulation and improvement, The effect of promoting target organ agonists and promoting the differentiation of myeloid cells

Inactive Publication Date: 2011-09-21
SHAANXI TIANKUI BIOMEDICAL TECH
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The efficacy of modern immunosuppressive agents in the treatment of severe aplastic anemia is similar to that of bone marrow transplantation, but the former cannot be cured and has long-term complications, such as clonal diseases, including MDS, PNH, and leukemia
[0009] (4) Hematopoietic cytokines and combined treatment for aplastic anemia is anemia caused by hematopoietic stem cell disease. The endogenous plasma EPO level is above 500u / L. Recombinant human EPO must be used in large doses to treat aplastic anemia. will have any effect
Recombinant human colony-stimulating factor including G-CSF, GM-CSF or IL-3 in the treatment of aplastic anemia may have some effect on increasing neutrophils and reducing infection, but it is not effective in improving anemia and thrombocytopenia, unless large doses are used
However, hematopoietic cytokines are expensive, so they are currently limited to adjuvant drugs in the treatment of severe aplastic anemia immunosuppressants, such as the use of ALG / ATG in the treatment of severe aplastic anemia, often due to severe neutropenia and concurrent infection, leading to early death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine controlling and curing chronic aplastic anemia
  • Medicine controlling and curing chronic aplastic anemia
  • Medicine controlling and curing chronic aplastic anemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Drugs for preventing and treating chronic aplastic anemia, including 12% hexadecenoic acid, 9.0% hexadecenoic acid, 15.3% 9-octadecenoic acid, 4.6% octadecanoic acid, 26% by weight % 9,12-octadecadienoic acid and 33.1% 9,12,15-octadecatrienoic acid. The palmitic acid is isolated, extracted and prepared from natural plants Eucommia Eucommia, Eucommia eucalyptus, the seeds of the safflower fruit of the medicinal Compositae plant of the dicotyledonous plant, the seed skin oil of Zanthoxylum bungeanum, the stems and leaves of seabuckthorn or the whole fruit. The hexadecenoic acid is isolated, extracted and prepared from natural plants Eucommia ulmoides, eucommia, the seeds of the safflower fruit of the medicinal Compositae plant of the dicotyledonous plant, the seed skin oil of Zanthoxylum bungeanum, the stems and leaves of seabuckthorn or the whole fruit. The 9-octadecenoic acid is isolated, extracted and prepared from natural plants Eucommia Eucommia, Eucommia eucalyptus,...

Embodiment 2

[0056] The medicine for preventing and treating chronic aplastic anemia comprises 32% hexadecanoic acid, 10.0% hexadecenoic acid, 20% 9-octadecenoic acid, 5.6% octadecanoic acid, 10 % of 9,12-octadecadienoic acid and 22.4% of 9,12,15-octadecatrienoic acid. The palmitic acid is isolated, extracted and prepared from natural plants Eucommia Eucommia, Eucommia eucalyptus, the seeds of the safflower fruit of the medicinal Compositae plant of the dicotyledonous plant, the seed skin oil of Zanthoxylum bungeanum, the stems and leaves of seabuckthorn or the whole fruit. The hexadecenoic acid is isolated, extracted and prepared from natural plants Eucommia ulmoides, eucommia, the seeds of the safflower fruit of the medicinal Compositae plant of the dicotyledonous plant, the seed skin oil of Zanthoxylum bungeanum, the stems and leaves of seabuckthorn or the whole fruit. The 9-octadecenoic acid is isolated, extracted and prepared from natural plants Eucommia Eucommia, Eucommia eucalyptus,...

Embodiment 2

[0057] For Example 2, a rat leukopenia model induced by cyclophosphamide was used: wistar rats, weighing 200-240 g, male and female. Rats were injected intraperitoneally with cyclophosphamide 40 mg / kg daily for 5 consecutive days to establish a leukopenia model. Drugs were given to each drug group of model animals: high drug dose group, medium dose drug group, low drug dose group, positive drug (cyclophosphamide) group, model group, and blank control group. The measured results are shown in Table 6, Table 7 and Table 8:

[0058] Table 6 Comparison of serum hemoglobin, leukocytes, platelets, and bone marrow levels in each group of rats after administration (X ± S)

[0059]

[0060] Note: The above α=0.05 is the standard of statistical significance. compared with the model group; * P** P<0.01

[0061] Table 7 Comparison of serum androgen and growth hormone levels in each group of rats after administration (X ± S)

[0062]

[0063] Note: The above α=0.05 is the standar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a medicine controlling and curing chronic aplastic anemia. The medicine is composed of a mixture comprising, by weight percentage, 12 to 32 percent of hexadecanoic acid , 9.0 to 34 percent of hexadecylenic acid, 15.3 to 32 percent of 9-octadecenoic acid, 0.3 to 4.6 percent of stearic acid, 10.8 to 26 percent of 9, 12-octadecadienoic acid and 3.6 to 36 percent of 9,12,15- octadecatrienoic acid. Compared to other medicines, the medicine has simple components and possesses effects of activating marrow hematopoiesis, promoting marrow cell fifferentiation and being a target organ stimulant. The medicine can achieve the effect of adjusting and improving hematopoiesis microenvironment and helping a body perform multi-way signal transduction. The medicine is characterized by good curative effect, safety and simplicity.

Description

technical field [0001] The invention belongs to the field of fatty acid raw material medicines which are composed of fatty acids extracted from natural plants and are compatible according to the compositional ratio of the content of the fatty acids, and specifically relates to a medicine for preventing and treating chronic aplastic anemia. Background technique [0002] Aplastic anemia is a rare, serious blood system disease whose etiology and pathological mechanism are not very clear, and its acute case fatality rate is high. Since aplastic anemia is characterized by pancytopenia as the main clinical manifestation, which seriously affects the quality of life of patients, especially in recent years, with the increasing development of industry and the aggravation of environmental pollution, the incidence of aplastic anemia has gradually increased. Therefore, hematology work at home and abroad Researchers have conducted extensive research on the incidence, regional distribution...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/20A61K31/201A61K31/202A61P7/06
Inventor 魏霞蓁宋兰兰
Owner SHAANXI TIANKUI BIOMEDICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com